Want to see PTCT full AI Analyst Report?
PTCT Stock Chart & Stats
$72.43
>-$0.01(-0.02%)
At close: 4:00 PM EST
$72.43
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$43.18 - $90.87
Previous CloseN/A
Volume146.45K
Average Volume (3M)2.26M
Market Cap
$6.51B
Enterprise Value$4.12K
Total Cash (Recent Filing)$1.89B
Total Debt (Recent Filing)$395.09M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Jul 30, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding82,949,340
10 Day Avg. Volume1,946,341
30 Day Avg. Volume2,261,249
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio8.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$99.30Price Target Upside37.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.52
Revenue Forecast (FY)$1.18B
Bulls Say, Bears Say
Bulls Say
Sephience Commercial MomentumSustained, accelerating launch metrics indicate durable product-market fit and scalable commercial execution. Strong prescription cadence, high refill rates and expanding country rollout support recurring product revenue, reduce single-product launch risk and underpin multi-year revenue growth potential.
Strong Liquidity PositionNearly $1.9B in cash and securities provides a multi-quarter buffer to fund commercialization, clinical trials, and operating variability without immediate dilutive capital raises. This liquidity supports strategic optionality and execution of the Sephience rollout and near-term pipeline activities.
Clinical Pipeline Validation (votoplam)Robust 24-month data and a partner‑led Phase 3 materially de‑risks a lead neuroscience asset. Positive efficacy and a Novartis partnership increase likelihood of regulatory success, potential milestone payments, and downstream royalties, strengthening long‑term pipeline value beyond current product sales.
Bears Say
Negative Stockholders' Equity And LeveragePersistently negative equity and meaningful debt constrain financial flexibility, distort return metrics, and raise refinancing and covenant risks. This structural weakness can increase cost of capital, limit strategic choices, and make future financing or M&A more dilutive or expensive.
Volatile Cash Flow And Recent TTM BurnLarge swings between surplus and burn reduce predictability of internal funding for launches and trials. Inconsistent cash generation forces reliance on external financing and complicates long-term planning for commercialization and development spend, elevating execution risk.
Legacy Product Concentration And Erosion RiskDependence on uneven orders and aging DMD franchise revenue increases top-line volatility as one-offs and generic competition reduce recurring sales. This structural exposure weakens baseline revenue stability while the new launch scales, pressuring near-term margin and cash forecasts.
PTC Therapeutics News
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $43.17 and its highest was $90.87 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $6.51B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 13 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.442.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is 0.22.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 82,949,340 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went up 14.266%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PTC Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.30 (37.10% Upside)
$99.30 (37.10% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 130.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 17.1%
Last 30 Days ▲ 17.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.10%
12-Months-Change
Fundamentals
Return on Equity
99.84%
Trailing 12-Months
Asset Growth
8.05%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
PTCT Stock 12 Month Forecast
Average Price Target
$99.30
▲(37.10% Upside)
Technical Analysis
Ownership Overview
1.44% Insiders
27.54% Mutual Funds
0.07% Other Institutional Investors
41.96% Public Companies and
Individual Investors